"""
Question: 1101 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients, from four care centres in four semi-rural localities of the RC (regional hospitals in Ouesso and Owando in the north, and regional hospitals in Dolisie and Sibiti in the south of the country, Figure 1 ). Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, reverse transcriptase and integrase genes, respectively.

Rationale: The study collected and analyzed new patient samples during 2019–2020 and deposited newly generated sequences in GenBank, indicating previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: From the 85 samples that were successfully amplified, subsequent Sanger sequencing was performed. Altogether, 76 samples were sequenced for the RT region, 68 for the PR, and 46 for the INT.

Rationale: The paper explicitly reports sequencing results for HIV-1 RT, PR, and INT regions, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Viral RNA was extracted from plasma samples using the High Pure Viral RNA Kit (Roche Diagnostics Systems ®, Nutley, State of New Jersey, USA), following the manufacturer's protocol, and stored at −80 °C until further use. PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer.

Rationale: Methods describe direct extraction and sequencing from patient plasma without any description of cell culture or serial passaging, indicating no in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. The genotypic susceptibility score (GSS) ... was calculated ... by summing the individual resistance scores for each line drug in the combination ART regimen.

Rationale: The study reports genotypic (sequence-based) resistance analysis and calculated GSS; there is no mention of phenotypic susceptibility testing (e.g., IC50 assays), thus no in vitro antiretroviral susceptibility data.

Answer: No
"""

"""
Question: 2101 

Evidence: Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, reverse transcriptase and integrase genes, respectively. Data Availability Statement: Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, re-verse transcriptase and integrase genes, respectively.

Rationale: The paper explicitly lists GenBank accession numbers for the sequenced strains.

Answer: Yes
"""

"""
Question: 2102 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients, from four care centres in four semi-rural localities of the RC. Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, reverse transcriptase and integrase genes, respectively.

Rationale: The accession numbers correspond to sequences obtained from clinical patient samples (not laboratory strains).

Answer: Yes
"""

"""
Question: 2103 

Evidence: Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, reverse transcriptase and integrase genes, respectively. Data Availability Statement: Accession numbers to the GenBank database for sequenced HIV-1 strains were OK180621-OK180687, OK180688-OK180764 and OK180765-OK180811 for protease, re-verse transcriptase and integrase genes, respectively.

Rationale: The paper lists three continuous ranges of GenBank accession numbers for PR, RT, and INT sequences.

Answer: OK180621-OK180687; OK180688-OK180764; OK180765-OK180811
"""

"""
Question: 2202 

Evidence: Altogether, 76 samples were sequenced for the RT region, 68 for the PR, and 46 for the INT. The most frequent mutations conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs) were M184V/I with a prevalence of 37%, followed by T215Y/F/S/V at 18%.

Rationale: The paper reports aggregate mutation frequencies across samples rather than per-sample mutation lists, indicating it does not provide lists of mutations for individual isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: All patients were previously diagnosed with HIV-1 using the national testing algorithm, which included two rapid assays, and were all ART-experienced. HIV-1 plasma viral load was evaluated by RT-qPCR with the COBAS ® 6800 System.

Rationale: The study exclusively involves HIV-1-infected patients.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The global analysis of this pol region showed that HIV-1 CRF02_AG was the predominant subtype with a prevalence of about 22% ( Figure 2 ), followed by subtype A4 (15%). We also observed high diversity, including pure subtypes and recombinant forms in CRF37_cpx (11%), A1 (9%), G (8%), CRF45_cpx (7%), H (6%), CRF11_cpx (4%), D (4%), and in subtypes with less than 4%, CRF75_BF, CRF13_cpx, J, CRF25_cpx, CRF18_cpx, CRF47_BF, CRF06_cpx, F2 and CRF09_cpx.

Rationale: The paper lists the subtypes and CRFs identified from pol sequencing.

Answer: CRF02_AG; A4; CRF37_cpx; A1; G; CRF45_cpx; H; CRF11_cpx; D; CRF75_BF; CRF13_cpx; J; CRF25_cpx; CRF18_cpx; CRF47_BF; CRF06_cpx; F2; CRF09_cpx
"""

"""
Question: 2303 

Evidence: For the identification of HIV-1 subtype and drug-associated resistance mutations, reverse transcriptase (RT), protease (PR), and integrase (INT) coding regions were amplified. Altogether, 76 samples were sequenced for the RT region, 68 for the PR, and 46 for the INT.

Rationale: The sequenced genes are explicitly stated as RT, PR, and INT.

Answer: Protease (PR), Reverse Transcriptase (RT), Integrase (INT)
"""

"""
Question: 2304 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. Altogether, 76 samples were sequenced for the RT region, 68 for the PR, and 46 for the INT.

Rationale: The pol region (which includes PR, RT, INT) was sequenced and analyzed.

Answer: Yes
"""

"""
Question: 2401 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients ... from four care centres in four semi-rural localities of the RC (regional hospitals in Ouesso and Owando in the north, and regional hospitals in Dolisie and Sibiti in the south of the country, Figure 1 ). We included 210 patients in this study.

Rationale: Sequences originated from the Republic of the Congo, specifically the four localities: Ouesso, Owando, Dolisie, and Sibiti.

Answer: Republic of the Congo (Ouesso, Owando, Dolisie, Sibiti)
"""

"""
Question: 2402 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients. Plasma samples were collected, and viral RNA was extracted.

Rationale: The sampling period is explicitly given as 2019–2020.

Answer: 2019–2020
"""

"""
Question: 2502 

Evidence: PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer. Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region.

Rationale: Sequencing was performed using Sanger technology.

Answer: Yes
"""

"""
Question: 2503 

Evidence: PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer. Accordingly, minority variants could not be detected and only mutations present at minimum frequencies above 15% to 20% of the viral quasi-species were monitored.

Rationale: The use of Sanger sequencing and the stated detection limits indicate that no NGS technology was used.

Answer: No
"""

"""
Question: 2504 

Evidence: PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer. Accordingly, minority variants could not be detected and only mutations present at minimum frequencies above 15% to 20% of the viral quasi-species were monitored.

Rationale: Direct bulk PCR product sequencing was used without mention of cloning; the inability to detect minority variants supports that samples were not cloned prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Our analyses were performed using routine Sanger sequencing that does not allow for the detection of minority viral variants that comprise less than 20% of the viral population in a patient sample. PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer.

Rationale: Single-genome sequencing would detect minority variants more sensitively; the paper states routine bulk Sanger sequencing, not SGA.

Answer: No
"""

"""
Question: 2506 

Evidence: PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer. For the identification of HIV-1 subtype and drug-associated resistance mutations, reverse transcriptase (RT), protease (PR), and integrase (INT) coding regions were amplified.

Rationale: There is no mention of molecular cloning; instead, bulk PCR amplicons were directly sequenced.

Answer: No
"""

"""
Question: 2601 

Evidence: Viral RNA was extracted from plasma samples using the High Pure Viral RNA Kit (Roche Diagnostics Systems ®, Nutley, State of New Jersey, USA), following the manufacturer's protocol. Altogether, 76 samples were sequenced for the RT region, 68 for the PR, and 46 for the INT.

Rationale: Sequencing was performed on viral RNA from plasma, indicating plasma HIV sequencing results are reported.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Viral RNA was extracted from plasma samples using the High Pure Viral RNA Kit (Roche Diagnostics Systems ®, Nutley, State of New Jersey, USA). For each patient included, approximately 4 mL of venous blood was collected into an EDTA tube ... The plasma samples (2 mL per patient) obtained after centrifugation were aliquoted.

Rationale: The study used plasma; PBMC-based proviral DNA sequencing is not described.

Answer: No
"""

"""
Question: 2603 

Evidence: Only samples from 85 patients were successfully amplified, consisting of 29 samples from Dolisie, 33 from Ouesso, 13 from Owando, and 10 from Sibiti ( Figure 1 ). From the 85 samples that were successfully amplified, subsequent Sanger sequencing was performed.

Rationale: A total of 85 patient plasma samples proceeded to amplification and sequencing workflow; these represent the plasma virus sequencing set.

Answer: 85
"""

"""
Question: 2604 

Evidence: Viral RNA was extracted from plasma samples using the High Pure Viral RNA Kit. There is no description of PBMC isolation or proviral DNA sequencing.

Rationale: Since only plasma RNA was sequenced, no PBMC virus sequencing was performed.

Answer: 0
"""

"""
Question: 2605 

Evidence: HIV-1 plasma viral load was evaluated by RT-qPCR ... with a limit of detection of 20 copies/mL. In addition, 35.3% of patients had a viral load above 100,000 copies/mL.

Rationale: High plasma viral loads indicate active HIV replication; sequences derived from plasma RNA correspond to actively replicating virus.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Viral RNA was extracted from plasma samples using the High Pure Viral RNA Kit. Our analyses were performed using routine Sanger sequencing that does not allow for the detection of minority viral variants ...

Rationale: The study sequenced plasma viral RNA rather than proviral DNA; hence, sequences were not from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: Before inclusion, fully informed consent was obtained from each patient, and informed consent was obtained from the parents or legal guardians of younger patients. Age, years Mean (min–max) 44 (6–72).

Rationale: The presence of participants as young as 6 years and mention of parental consent indicate inclusion of children.

Answer: Yes
"""

"""
Question: 2702 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients ... from four care centres in four semi-rural localities of the RC. All these centres provide medical consultations and ARV supplies free of charge to patients, except for biological monitoring.

Rationale: The paper describes an observational cross-sectional study in routine care settings, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients ... from four care centres in four semi-rural localities of the RC. All these centres provide medical consultations and ARV supplies free of charge to patients, except for biological monitoring.

Rationale: As it was not a clinical trial, not all individuals (indeed none) were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Only samples from 85 patients were successfully amplified, consisting of 29 samples from Dolisie, 33 from Ouesso, 13 from Owando, and 10 from Sibiti ( Figure 1 ). From the 85 samples that were successfully amplified, subsequent Sanger sequencing was performed.

Rationale: The number of individuals with samples that proceeded to sequencing is 85.

Answer: 85
"""

"""
Question: 3102 

Evidence: We included 210 patients in this study. Only samples from 85 patients were successfully amplified ... From the 85 samples that were successfully amplified, subsequent Sanger sequencing was performed.

Rationale: Not all included individuals had successful amplification/sequencing; only 85/210 did.

Answer: No
"""

"""
Question: 4101 

Evidence: All patients ... were all ART-experienced. Therefore, due to the lack of virological and immunological monitoring in these regions (no viral load or CD4 count), the selection concerned only patients with clinical failure according to the WHO recommendations.

Rationale: The cohort excluded ART-naive individuals; all were ART-experienced.

Answer: No
"""

"""
Question: 4102 

Evidence: All patients ... were all ART-experienced. The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI).

Rationale: Sequenced individuals had prior antiretroviral exposure.

Answer: Yes
"""

"""
Question: 4103 

Evidence: All patients ... were all ART-experienced. From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients.

Rationale: The study did not include ART-naive individuals, only ART-experienced ones.

Answer: No
"""

"""
Question: 4104 

Evidence: All patients ... were all ART-experienced. From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients.

Rationale: There were no ART-naive individuals; therefore, the number of samples from ART-naive individuals is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI). Finally, 42.4% of patients were on ART for more than 48 months.

Rationale: The paper provides summary current regimens and duration categories but does not provide complete per-individual ART histories for all participants.

Answer: No
"""

"""
Question: 4201 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients. All patients ... were all ART-experienced.

Rationale: Transmitted drug resistance is typically assessed in ART-naive or newly diagnosed individuals; this study excluded such individuals.

Answer: No
"""

"""
Question: 4202 

Evidence: All patients ... were all ART-experienced. From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients, excluding newly diagnosed patients.

Rationale: Pretreatment resistance (before starting ART) is not assessable here because all participants were already on ART.

Answer: No
"""

"""
Question: 4301 

Evidence: According to the 2016 WHO guidelines, a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) is recommended as a first-line regimen, and two NRTIs and one protease inhibitor (PI) as second-line therapy. The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI).

Rationale: The regimens included NRTIs, NNRTIs, PIs, and INSTIs (dolutegravir).

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302 

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI). In the RC, DTG, an INSTI, was recommended in 2020 but is currently not available all over the country.

Rationale: The paper reports that 17.6% received DTG, an integrase inhibitor.

Answer: Yes
"""

"""
Question: 4303 

Evidence: (ABC or AZT) + 3TC + LPV/r. Because protease inhibitors were not often used (4.7%, Table 1 ), the major PI mutations responsible for drug resistance (I47V and L76V) were mostly rare and accounted for at less than 5%.

Rationale: The regimen list includes LPV/r (a PI), and usage is quantified at 4.7%.

Answer: Yes
"""

"""
Question: 4304 

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and ... 17.6% ... received a DTG-containing regimen ... Finally, 4.7% ... (ABC or AZT) + 3TC + LPV/r. Current ART regimens ... [Table 1 shows multiple distinct regimens and proportions].

Rationale: Multiple different regimens were used, so not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI). Interestingly, even if 17.6% of the patients received DTG as part of their regimen, no major INSTI mutation was observed.

Rationale: Some participants received DTG; therefore, not all were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: Current ART regimens [Table 1] list AZT+3TC+(NVP or EFV), TDF+3TC+EFV, DTG+3TC+(ABC or TDF), and (ABC or AZT)+3TC+LPV/r. The paper does not provide prior regimen histories for individuals.

Rationale: The study reports only current regimens and does not state how many individuals had regimen changes or multiple regimens historically.

Answer: NA
"""

"""
Question: 4404 

Evidence: Current ART regimens [Table 1] list several options with proportions, but no per-individual longitudinal regimen histories are provided. Another limitation arose from the lack of data on treatment adherence.

Rationale: Without regimen history per person, the number who received more than two regimens cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: Current ART regimens are summarized as group proportions rather than per-person histories. The paper does not report the number of distinct regimens per individual.

Rationale: The number of regimens per individual is not provided; thus it cannot be determined if all received the same number.

Answer: NA
"""

"""
Question: 4406 

Evidence: Current ART regimens are presented as a cross-sectional snapshot (Table 1). The study does not report whether individuals had prior regimen changes.

Rationale: The paper does not state whether all individuals had only one regimen; this cannot be determined.

Answer: NA
"""

"""
Question: 4501 

Evidence: DTG+3TC + (ABC or TDF) 15 (17.6). The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI).

Rationale: Table 1 shows 15 individuals on DTG-containing regimens, corresponding to 17.6% of 85.

Answer: 15
"""

"""
Question: 4502 

Evidence: (ABC or AZT) + 3TC + LPV/r 4 (4.7). The paper lists LPV/r as the PI used and does not mention darunavir in any regimen.

Rationale: Darunavir is not reported among the regimens; therefore, the number receiving darunavir is zero.

Answer: 0
"""

"""
Question: 5101 

Evidence: As expected, and according to the treatment of the patients and the viral load measured, we observed the presence of drug resistance mutations for all patients. Most patients presented an accumulation of mutations conferring resistance against NRTIs, NNRTIs and PIs.

Rationale: Within the set of successfully analyzed patients, the paper states all had one or more resistance mutations.

Answer: 85
"""

"""
Question: 5102 

Evidence: Interestingly, even if 17.6% of the patients received DTG as part of their regimen, no major INSTI mutation was observed. Still, T97A (38%) and L74I (38%) were abundantly selected.

Rationale: The study explicitly reports no major (primary) INSTI resistance mutations; accessory polymorphisms were observed but not counted as major resistance.

Answer: 0
"""

"""
Question: 5103 

Evidence: Additional mutations were also observed at lower frequencies such as ... K65R (4%) ... and Y115F (2%). The M184V mutation increases susceptibility to TDF and AZT, while simultaneously limiting the emergence of drug resistance to both molecules.

Rationale: Although TDF-associated mutations (e.g., K65R) are reported by percentage, the exact number of individuals is not provided and overlap is unknown.

Answer: NA
"""

"""
Question: 5104 

Evidence: Still, T97A (38%) and L74I (38%) were abundantly selected. Additionally, mutations N144D, V151L and E157Q were less frequently observed, with a prevalence of 5% each.

Rationale: These are the INSTI-associated mutations observed in the integrase gene; no major INSTI resistance mutations were detected, but these accessory/polymorphic mutations were reported.

Answer: T97A; L74I; N144D; V151L; E157Q
"""

"""
Question: 6101 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. The genotypic susceptibility score (GSS) ... was calculated ...

Rationale: The study performed genotypic analyses and did not conduct phenotypic susceptibility testing, so no method applies.

Answer: NA
"""

"""
Question: 6102 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. Our analyses were performed using routine Sanger sequencing that does not allow for the detection of minority viral variants ...

Rationale: The paper reports no IC metrics; it only presents genotypic data and GSS.

Answer: No
"""

"""
Question: 6103 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. The genotypic susceptibility score (GSS) ... was calculated ...

Rationale: No fold-change IC50 data are presented; only genotypic interpretations and GSS are provided.

Answer: No
"""

"""
Question: 6104 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer.

Rationale: No phenotypic assay was used; only genotypic sequencing and interpretation were performed.

Answer: NA
"""

"""
Question: 6105 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. The genotypic susceptibility score (GSS) ... was calculated ...

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Finally, drug resistance genotyping and phylogenetic analysis were conducted following Sanger sequencing of the pol region. The genotypic susceptibility score (GSS) ... was calculated ...

Rationale: No phenotypic susceptibility testing was performed; thus, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Viral RNA was extracted from plasma samples ... For the identification of HIV-1 subtype and drug-associated resistance mutations, reverse transcriptase (RT), protease (PR), and integrase (INT) coding regions were amplified. PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer.

Rationale: The sequences are derived from patient samples; there is no mention of constructing site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: From 2019 to 2020, we conducted a cross-sectional study of HIV-1-infected patients ... Plasma samples were collected, and viral RNA was extracted. PCR products were processed by Sanger sequencing on both strands using an Applied Biosystems 3500xl Dx Genetic Analyzer.

Rationale: The study sequenced clinical samples directly with no in vitro passaging described.

Answer: No
"""